Evolent Health Q4 revenue $556M, FY revenue $1.96B (+45%); net loss ($142M), adj EBITDA $194.7M (+84%)

Evolent Health, Inc.

2023-FY EPS reported -$1.28 revenue$556,055,000

Full year 2023 revenue of $1,963.9M, up 45% YoY; net loss of $(142.3)M (net loss margin -7.2%).
Adjusted EBITDA of $194.7M, up 84% YoY; cash flow from operations of $142.6M.
Q4 2023 revenue $556.1M, net loss $(41.4)M, adjusted EBITDA $48.1M (8.6% margin).
Initial 2024 outlook: revenue growth ~25% at midpoint, consistent with long-term targets.
Announced four new revenue agreements, including first comprehensive oncology bundle and first Performance Suite for advanced imaging.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolent Health, Inc. updated its 2024 guidance (initiated).

Period: 2024
Guidance: initiated
Result: guidance update

Exact text from the filing

Provides initial outlook for 2024 in line with long-term targets

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evolent Health, Inc. reported the quarter and year ended December 31, 2023 results: revenue $556,055 thousand, $1,963,896 thousand, net income ($41,395) thousand, ($142,260) thousand.

Period: the quarter and year ended December 31, 2023
Revenue: $556,055 thousand, $1,963,896 thousand
Net income: ($41,395) thousand, ($142,260) thousand
Result: reported results

Exact text from the filing

Evolent Announces Fourth Quarter and Full Year 2023 Results • Full year revenue of $1,963.9 million, 45% growth over 2022 • Net loss attributable to common shareholders of Evolent Health, Inc. of $(142.3) million

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.